A total of 351 women ( 177 in the pegfilgrastim group and 174 in the placebo group ) between 20 and 69 years of age with stage I-III invasive breast carcinoma who were to receive TC chemotherapy ( docetaxel 75 mg/m ( 2 ) and cyclophosphamide 600 mg/m ( 2 ) every 3 weeks ) as either neoadjuvant or adjuvant therapy were enrolled ; 346 of these patients were treated with either pegfilgrastim ( n = 173 ) or placebo ( n = 173 ) .